There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alnylam Pharma (ALNY – Research Report), Praxis Precision Medicines (PRAX – Research Report) and SAB Biotherapeutics (SABS – Research Report) with bullish sentiments.
Alnylam Pharma (ALNY)
In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Alnylam Pharma, with a price target of $395.00. The company’s shares closed last Friday at $189.38.
According to TipRanks.com, Trucchio has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Alnylam Pharma is a Moderate Buy with an average price target of $233.83, which is a 22.9% upside from current levels. In a report issued on January 2, Bernstein also maintained a Buy rating on the stock with a $220.00 price target.
See the top stocks recommended by analysts >>
Praxis Precision Medicines (PRAX)
H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Praxis Precision Medicines today and set a price target of $105.00. The company’s shares closed last Friday at $25.19.
According to TipRanks.com, Tsao is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Praxis Precision Medicines with a $135.25 average price target.
SAB Biotherapeutics (SABS)
In a report released today, Edward White from H.C. Wainwright reiterated a Buy rating on SAB Biotherapeutics, with a price target of $10.00. The company’s shares closed last Friday at $5.82.
According to TipRanks.com, White is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for SAB Biotherapeutics with a $6.50 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ALNY:
- The Smid-cap biotech stocks to own in 2024, according to Bernstein
- Alnylam price target raised to $220 from $216 at Bernstein
- William Blair sees ATTR-PN market as large enough for two players
- Citi says approval ‘likely’ for Ionis’ eplontersen ATTR-PN NDA
- Alnylam price target raised by $7 at Piper Sandler, here’s why
